Completed psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Completed is a registry status. The study has ended normally and participants are no longer being followed up. Status is reported by the study team and can change.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 400 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 96 |
| MDMA | 62 |
| LSD | 29 |
| DMT | 24 |
| 5-MeO-DMT | 11 |
| Ayahuasca | 4 |
| Ketamine | 201 |
| Mescaline | 2 |
| Ibogaine | 5 |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 28 | 7% |
| Phase 1 | 129 | 32% |
| Phase 2 | 113 | 28% |
| Phase 3 | 27 | 7% |
| Phase 4 | 28 | 7% |
| Not applicable | 52 | 13% |
| Not reported | 23 | 6% |
Countries
Country is taken from the study's linked research site. 3 of 400 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 223 | 56% |
| Switzerland | 51 | 13% |
| United Kingdom | 23 | 6% |
| Canada | 20 | 5% |
| France | 9 | 2% |
| Netherlands | 7 | 2% |
| Brazil | 6 | 2% |
| China | 6 | 2% |
| Argentina | 5 | 1% |
| Australia | 5 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 43 |
| 2020 to 2023 | 145 |
| 2015 to 2019 | 111 |
| 2010 to 2014 | 72 |
| Before 2010 | 29 |
Study design
- 377 interventional and 23 observational studies.
- Median planned or actual enrolment is 29 participants (range 3 to 1,806, across 400 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 149 |
| Healthy volunteers | 42 |
| Trauma and PTSD | 33 |
| Other substance use | 25 |
| Suicidal thoughts | 23 |
| Anxiety | 17 |
| Alcohol use | 12 |
| Cancer and end of life | 12 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07540494 | Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects | Completed | Phase 1 | United States | 2026-04 |
| NCT06905652 | Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants | Completed | Phase 1 | Switzerland | 2025-07 |
| NCT07050368 | A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers | Completed | Phase 1 | United Kingdom | 2025-07 |
| NCT07273851 | Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy | Completed | Not applicable | Panama | 2025-07 |
| NCT07526454 | Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder | Completed | Not applicable | Egypt | 2025-07 |
| NCT07061886 | Drug Effects on Mood and Behavior - Expectancy | Completed | Early Phase 1 | United States | 2025-06 |
| NCT06795659 | Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder) | Completed | Phase 1 | United States | 2025-06 |
| NCT07017478 | Mood Effects of Serotonin Agonists: Depression | Completed | Early Phase 1 | United States | 2025-06 |
| NCT07053345 | A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression | Completed | Phase 4 | South Korea | 2025-06 |
| NCT07193901 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior | Completed | Phase 2 | China | 2025-05 |
| NCT06821087 | Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19 | Completed | Phase 2 | United States | 2025-04 |
| NCT06835699 | Psilocybin Brain Stimulation and Imaging Pilot Study | Completed | Phase 1 | United States | 2025-04 |
| NCT06884514 | Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects | Completed | Phase 1 | Switzerland | 2025-04 |
| NCT06180759 | Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants | Completed | Phase 1 | Switzerland | 2025-01 |
| NCT06647056 | Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures | Completed | Not applicable | France | 2024-12 |
| NCT06812221 | Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | Completed | Phase 1 | Argentina | 2024-12 |
| NCT06726382 | KF2024#1-trial: Esketamine Interaction Study | Completed | Phase 1 | Finland | 2024-12 |
| NCT06450210 | Safety for Home Administration of Microdose Psilocybin Use | Completed | Phase 1 | United States | 2024-12 |
| NCT06746441 | Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers | Completed | Phase 2 | Pakistan | 2024-12 |
| NCT06644170 | A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | Completed | Phase 1 | United States | 2024-11 |
| NCT06650800 | Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression | Completed | Not applicable | France | 2024-11 |
| NCT06620042 | FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression | Completed | Phase 2 | United States | 2024-11 |
| NCT06643637 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants | Completed | Phase 1 | Australia | 2024-11 |
| NCT06816667 | Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | Completed | Phase 1 | Argentina | 2024-10 |
| NCT06299319 | Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD | Completed | Phase 1 | Canada | 2024-09 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable